FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs

FDA clears narrow use of Lynparza in prostate cancer, continuing ‘shift’ on PARP drugs

Source: 
BioPharma Dive
snippet: 

The Food and Drug Administration on Wednesday approved AstraZeneca and Merck & Co.’s Lynparza for use in certain people newly diagnosed with advanced prostate cancer.